相关实验视频
Updated: Sep 19, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.5K
身体活动,病理生理学和认知之间的相互作用.
Marcos Olvera-Rojas1, Francisco B Ortega2, Irene Esteban-Cornejo3
1Department of Physical Education and Sports, Faculty of Sport Sciences, Sport and Health University Research Institute (iMUDS), University of Granada, Granada, Spain.
Trends in neurosciences
|June 6, 2025
概括
定期的体力活动 (PA) 可能会预防阿尔茨海默病 (AD). 较高的PA水平与较低的化 (ptau) 217水平相关,这表明与病理和更好的认知功能有联系.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 公共卫生 公共卫生
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 身体活动 (PA) 是影响AD风险的可改变因素之一.
- 新出现的证据表明,PA和AD神经病理学之间存在联系.
研究的目的:
- 调查身体活动水平与阿尔茨海默病生物标志物之间的关联.
- 探索PA,病理生理学和AD的认知功能之间的关系.
主要方法:
- 横截面研究设计. 截面研究设计.
- 评估身体活动水平.
- 测量大脑脊髓液 (CSF) 或化陶 (ptau) 217度的血.
- 评估大脑对β-粉样蛋白 (Aβ) 的吸收.
- 认知功能的评估.
主要成果:
- 较高的体力活动水平与降低的ptau-217度有显著的关联.
- 这种关联在调整大脑摄取β-粉样蛋白 (Aβ) 后仍然显著.
- PA和降低的ptau-217之间的关系介导了更好的一般认知表现.
结论:
- 身体活动可以通过影响病理生理学来对阿尔茨海默病产生保护作用.
- 帕是缓解AD进展和维护认知功能的潜在治疗标.
相关概念视频
Alzheimer's Disease: Overview
686
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
686
Cognitive Development During Adulthood
312
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
312
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
214
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
214
Dementia
182
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
182

